FDA Citizen Petition Process: Filing, Review, and Appeals

The FDA citizen petition process lets any person or organization formally ask the Food and Drug Administration to issue, change, or revoke a regulation or take other administrative action. The right sits in 21 CFR 10.30, and the agency must respond to a properly filed petition within 180 days.¹ People use it for drug safety concerns, food labeling changes, medical device standards, and any other matter within the FDA’s authority.

What Your Petition Must Contain

21 CFR 10.30 prescribes a specific format. Skip a required section or use the wrong structure and the petition can be rejected before anyone weighs the substance.¹ There are five components.

Action Requested

Say exactly what you want the FDA to do. Issue a new regulation, amend a label, revoke an approval, order a study. Precision matters. “Improve drug safety” gives the agency nothing to act on. “Require a black box warning on Product X based on the following adverse event data” gives it something to evaluate.

Statement of Grounds

This is the core of the petition. You present the factual evidence and the legal basis for the request: scientific studies, clinical data, adverse event reports, and the statutory authority the FDA would use to act, typically under the Federal Food, Drug, and Cosmetic Act or the Public Health Service Act.¹

One requirement catches many petitioners off guard. The regulation obligates you to include representative information unfavorable to your own position. You cannot present only the data that supports your argument. Ignoring this undermines credibility with the reviewers evaluating your case.

Environmental Impact

Every petition must address whether the requested action would significantly affect the environment. Most petitioners claim a categorical exclusion, meaning the action falls into a category the FDA has already determined does not normally require environmental review. If no exclusion applies, you must include a full environmental assessment. The requirement flows from the National Environmental Policy Act.¹

Economic Impact

An economic impact analysis is not required upfront. The FDA asks for it only after reviewing the petition, if the agency decides it needs to understand the financial consequences of the proposed action.¹

Certification

The petitioner signs a certification attesting that the petition includes all information and views relied on and all representative unfavorable data known to the petitioner. False statements to a federal agency can carry legal consequences. The certification must include your signature, printed name, mailing address, and telephone number.¹

How to File

Most petitioners file electronically through Regulations.gov, which is faster and generates an automatic tracking number. The FDA maintains a dedicated docket, FDA-2013-S-0610, for citizen petition submissions. Navigate to that docket, select “Comment,” and upload your petition and attachments. The portal labels the process as submitting a “comment” because it uses shared infrastructure, but the filing is a formal petition.²

For paper filing, mail three complete copies of the petition and all attachments to: Dockets Management Staff, 5630 Fishers Lane, Room 1061, Rockville, MD 20852.³ Once processed, the FDA assigns a docket number you will use to track progress and reference the petition in any later correspondence or legal filing.¹

What Happens After You File

Your petition goes into a public docket that anyone can read and comment on. Industry groups, consumer advocates, researchers, and other interested parties routinely weigh in, and those comments become part of the record the FDA considers. The comment period typically runs 180 days, though the sponsoring FDA center can adjust it depending on the petition’s nature.⁴

Within 180 days of docketing, the FDA must respond. That response takes one of four forms: a full grant of the requested action, a partial grant, a denial, or an interim response explaining why the agency needs more time. Interim responses are common when a petition is scientifically complex or when the agency is juggling competing priorities.¹ When the FDA denies a petition, it issues a formal letter setting out the legal and scientific reasons. That letter becomes part of the public docket and establishes the administrative record, which matters if you later challenge the decision.

Withdrawing Before a Decision

You can withdraw a pending petition at any time before the FDA rules, without the agency’s permission and without prejudice to filing again. Once the FDA has ruled or referred the matter for a formal hearing, withdrawal requires the Commissioner’s approval, and the Commissioner can grant it with or without prejudice.¹

Faster Clock for Petitions That Could Delay a Generic

If your petition could affect the approval of a pending generic drug application, a 505(b)(2) application, or a biosimilar application, it falls under Section 505(q) of the Federal Food, Drug, and Cosmetic Act and different rules apply. Congress created these rules to stop brand-name manufacturers from using the petition process to hold up cheaper competitors.⁵

The FDA must take final action on a 505(q) petition within 150 days, and the agency cannot extend that deadline for any reason, even with the petitioner’s consent.⁵ A petition is subject to 505(q) only when all of the following are true: it is filed in writing under 21 CFR 10.30 or 10.35; a related generic, 505(b)(2), or biosimilar application is pending with a user fee goal date on or before the 150-day deadline; the requested action could delay approval of that pending application; and no statutory exception applies. The exceptions are narrow. A petition filed by the generic or biosimilar applicant about its own application is excluded, as are petitions relating solely to 180-day exclusivity timing.⁶

A 505(q) petition also requires a more detailed certification. The petitioner must certify under penalty of perjury that the petition includes all information and views relied on, includes representative unfavorable data, and that reasonable steps were taken to uncover unfavorable information. The petitioner also has to disclose the date when the underlying information first became known and identify any payments received or expected in connection with filing.⁵ The FDA will not review a 505(q) petition unless the certification matches the statutory language almost verbatim, and a deficient certification cannot be fixed by supplement. The only option is to withdraw and refile, which restarts the clock.⁶

The FDA can also summarily deny any 505(q) petition it determines was filed primarily to delay approval of a competing drug, when the petition fails to raise valid scientific or regulatory issues on its face. The agency weighs whether the petitioner sat on the information for an unreasonably long time, whether filing was suspiciously close to a competitor’s expected approval date, and whether the petitioner has a pattern of serial petitions raising the same issues. Beyond summary denial, the FDA can refer the matter to the Federal Trade Commission and report the finding to Congress.⁶

After a Denial: Reconsideration, Stay, and Court

A denial is not necessarily the end. You have two administrative options and one judicial one, each with its own deadline and rules.

Petition for Reconsideration

You have 30 days from the date of the decision to file a petition for reconsideration under 21 CFR 10.33. The Commissioner can also reconsider a decision on their own initiative at any time.⁷

Reconsideration is not a second bite at the apple. You cannot introduce new evidence outside the original administrative record. If you have new data, the proper route is a new petition. The Commissioner will grant reconsideration only when relevant information or views in the record were not previously or not adequately considered, the position is not frivolous, sound public policy grounds support reconsideration, and public health or other public interests do not outweigh it.⁷

Timing matters. You generally cannot file for reconsideration after you have already sued over the FDA’s decision. The Commissioner will refuse to consider a reconsideration petition once the matter is in court, with a narrow exception when a stay request has been denied and you have asked the reviewing court for a stay pending judicial review.⁷

Petition for Stay of Action

If the FDA takes or is about to take an action you believe is harmful, you can file a separate petition asking the agency to stay that action under 21 CFR 10.35. Filing deadline is 30 days from the decision you want stayed, though the Commissioner can accept late filings for good cause.⁸

Filing a stay petition does not automatically freeze anything. The FDA continues with its action unless the Commissioner affirmatively grants the stay, a statute requires one, or a court orders one. The Commissioner will grant a stay only when the petitioner would suffer irreparable injury, the request is made in good faith, there are sound public policy grounds, and the delay does not outweigh public health or other public interests. The petition itself must identify the specific decision being challenged, state how long a stay is needed, and set out the full factual and legal grounds.⁸

Judicial Review

Once the FDA has issued a final decision on your petition, reconsideration request, or stay petition, that decision is reviewable in federal court under the Administrative Procedure Act. You cannot skip ahead: administrative remedies must be exhausted first, and a premature lawsuit will draw a motion to dismiss on exhaustion grounds.⁹

Courts review FDA decisions under the arbitrary and capricious standard, asking whether the agency’s decision was reasonable and supported by the record, not whether the court would have reached the same conclusion.¹⁰ This is deferential. Courts do not re-weigh scientific evidence or substitute their judgment for the FDA’s. To prevail, you generally need to show the agency ignored relevant evidence, relied on factors Congress did not intend it to consider, or made a clear error of judgment.

1
eCFR. 21 CFR 10.30 – Citizen Petition
2
U.S. Food and Drug Administration. Instructions for Submitting Citizen Petitions (CPs) Electronically
3
U.S. Food and Drug Administration. Dockets Management
4
U.S. Food and Drug Administration. The FDA Docket Frequently Asked Questions
5
Office of the Law Revision Counsel. 21 USC 355 – New Drugs
6
U.S. Food and Drug Administration. Citizen Petitions and Petitions for Stay of Action Subject to Section 505(q) of the Federal Food, Drug, and Cosmetic Act
7
eCFR. 21 CFR 10.33 – Administrative Reconsideration of Action
8
eCFR. 21 CFR 10.35 – Administrative Stay of Action
9
eCFR. 21 CFR 10.45 – Court Review
10
Office of the Law Revision Counsel. 5 USC 706 – Scope of Review